2De Souza A, Ali -Shaw T, Reddy S M,et al. Inflammatory arthritis fol- lowing ustekinumab treatment for psoriasis : a report of two cases [ J ]. British Journal of Dermatology,2013,168:210.
3Poddubnyy D, Kay - Geert A, Johanna C, et aL Ustekinurnab for the treatment of patients with active ankylosing spondylitis : results of a 28 - week, prospective, open - label, proof - of - concept study (TOPAS) [J]. Ann Rheum Dis,2014,204:248.
4Raychaudhuri S P, Raychaudhuri S K, Genovese M C. IL- 17 receptor and its functional significance in psoriatic arthritis [ J ]. Molecular and Cellular Biochemistry ,2012,359:419.
5Chiricozzi A,Guttman - Yassky E,Su~trez - Farinas M,et al. Integrative responses to IL - 17 and TNF -α in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis[J]. Journal of Investi- gative Dermatology ,2011,131:677.
7Mclnnes I B, Sieper J, Braun J,et al. Efficacy and safety of secukinum- ab, a fully human anti -interleukin -17A monoclonal antibody, in pa- tients with moderate - to - severe psoriatic arthritis : a 24 - week, ran- domised, double - blind, placebo - controlled, phase II proof - of - con- cept trial[J]. Ann Rheum Dis ,2014,73:349.
8Papp K A, Langley R G, Sigurgeirsson B, et al. Efficacy and safety of secukinumab in the treatment of moderate - to - severe plaque psoriasis : a randomized, double - blind, placebo - controlled phase Ⅱ dose - ran- ging study[ J]. British Journal Dermatology, 2013,168:412.
10Krause C, Korchynskyi O, de Rooij K,et al. Distinct modes of inhibition by sclerostin on bone morphogenetic protein and Wnt signaling pathways [ J ]. Journal of Biological Chemistry ,2010,285 ( 53 ) : 1614.
二级参考文献185
1Mueller W,Herrmann B. Cyclosporin A for psoriasis[J].N Engl J Med, 1979,301 (10) :555.
2Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis [J].Nature, 2007,445 ( 7130 ) : 866 -873.
3Nestle FO, Kaplan DH, Barker J. Psoriasis [J]. N Engl J Med, 2009,361 (5) :496-509.
4Sugiyama H, Gyulai R, Toiehi E, et 'al. Dysfunctional blood and tar- get tissue CD4 + CD25high regulatory T cells in psoriasis: mecha- nism underlying unrestrained pathogenic effector T cell proliferation [ J ]. J Immuno1,2005,174 ( 1 ) : 164-173.
5Wilson N J, Boniface K, Chan JR,et al. Development, cytokine pro- file and function of human intedeukin 17-producing helper T cells [J]. Nat Irnmuno1,2007,8 ( 9 ) :950-957.
6Tracey D, Klareskog L, Sasso EH, et al. Tumor necrosis factor an- tagonist mechanisms of action : a comprehensive review [ J ]. Phar- macol Ther,2008,117 ( 2 ) :244-279.
7Krueger GG, Langley RG, Leonardi C, et al. A human interleukin- 12/23 monoclonal antibody for. the treatment of psoriasis [ J ]. N Engl J Med,2007,356(6) :580-592.
8Knight DM, Trinh H, Le J, et al. Construction and initial character- ization of a mouse-human chimeric anti-TNF antibody [J].Mol Im- munol, 1993,30 (16) :1443-1453.
9Menter A, Feldman SR, Weinstein GD, et al. A randomized com- parison of continuous vs. intermittent infliximab maintenance regi- mens over 1 year in the treatment of moderate-to-severe plaque pso- riasis[J]. J Am Acad Dermatol.2007 ,56(1 ):31 e31-e15.
10Reich K, Nestle FO, Papp K, et al. Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate-to-severe psoriasis : a randomized controlled trial [ J ]. Br J Dermato1,2006,154 ( 6 ) : 1161-1168.
